Washington, D.C. – On Tuesday, February 25, 2025, President Donald Trump signed an executive order aimed at significantly increasing price transparency within the American healthcare system. The order mandates that federal departments take assertive steps to enforce existing regulations requiring hospitals and insurers to disclose pricing information, building upon previous efforts initiated by his administration.
Directives and Departments Involved
The executive order specifically directs the departments of the Treasury, Labor, and Health and Human Services (HHS) to “rapidly implement and enforce” Trump’s previously established healthcare price transparency regulations. These regulations, first outlined during his prior term in office, seek to provide patients and employers with clear, comparable pricing data before receiving medical services.
The administration contends that the implementation and enforcement of these regulations were slowed during the subsequent Biden administration. As evidence of this, the White House referenced a 2023 lawsuit filed against the previous administration for its alleged failure to enforce specific prescription drug transparency requirements.
Key Requirements and Enforcement
A central tenet of the executive order is the demand for hospitals and insurers to disclose actual prices, rather than merely estimates. This distinction is crucial, as the administration argues that estimates can often deviate significantly from the final billed amount, hindering effective price shopping by consumers.
Furthermore, the order requires that pricing information be made comparable across different healthcare providers and insurers. This includes a specific mandate for transparency regarding prescription drug prices, an area often cited as opaque and contributing to high out-of-pocket costs for patients.
To ensure compliance, the executive order also mandates that the Treasury, Labor, and HHS departments update their enforcement policies. This directive underscores the administration’s intent to vigorously pursue entities that do not adhere to the transparency rules.
Administration’s Rationale and Expected Outcomes
According to statements released by the White House, the lack of price transparency in healthcare disproportionately benefits large corporate entities, particularly hospitals and insurance companies, allowing them to obscure costs and potentially charge inflated prices. By contrast, the administration posits that full transparency will lead to increased competition among providers and insurers, ultimately resulting in lower healthcare prices for patients and employers.
The White House maintains that empowering consumers with price information will enable them to make more informed decisions, facilitating shopping for healthcare services much like they would for other goods and services. This enhanced market dynamic is expected to drive down overall healthcare expenditures.
Evidence and Economic Projections Cited
The administration highlighted specific examples to illustrate the potential benefits of price transparency. One notable instance cited involves a patient in Wisconsin who reportedly saved $1,095 simply by shopping for two medical tests between two hospitals located within a 30-minute drive of each other. This example is presented as evidence that significant savings are attainable when price information is readily available.
The White House also referenced an economic analysis suggesting substantial potential savings upon the full implementation of the original Trump administration’s price transparency rules. This analysis estimates that consumers, employers, and insurers could collectively save up to $80 billion by 2025. The analysis further indicates that employers, in particular, could potentially reduce their healthcare costs by an average of 27% on 500 common medical services through improved price shopping facilitated by transparency.
Building on Previous Efforts
This latest executive order is not an isolated action but rather builds upon prior initiatives. It specifically references and expands upon Executive Order 13877, which President Trump signed on June 24, 2019, marking an earlier effort to promote healthcare price and quality transparency across the system.
By signing this new order, President Trump signals a renewed push to make healthcare costs more understandable and predictable for the American public, emphasizing the administration’s belief that greater transparency is a critical step towards controlling rising healthcare expenses and empowering individuals and businesses in the market.
